These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 32774071)
21. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345 [TBL] [Abstract][Full Text] [Related]
22. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes. Hien PN; Chun HJ; Oh JS; Kim SH; Choi BG J Gastrointest Oncol; 2024 Apr; 15(2):721-729. PubMed ID: 38756625 [TBL] [Abstract][Full Text] [Related]
23. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization. Wu Y; Zheng S; Zhang Z; Chen G; Chen X; Zheng T; Guo X; Chen H; Wang M; Xie X; Zhang B Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295504 [No Abstract] [Full Text] [Related]
24. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726 [TBL] [Abstract][Full Text] [Related]
25. Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liu H; Qin X; Jiang H; Sun C; Wu M; Xu Z; Lu T; Ma X; Han Z J Gastrointestin Liver Dis; 2022 Sep; 31(3):336-343. PubMed ID: 36112704 [TBL] [Abstract][Full Text] [Related]
26. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886 [TBL] [Abstract][Full Text] [Related]
27. Hepatic arterial infusion oxaliplatin plus raltitrexed and chemoembolization in hepatocellular carcinoma with portal vein invasion: A propensity score-matching cohort study. Chen S; Yuan B; Yu W; Wang X; He C; Chen C J Surg Oncol; 2022 Dec; 126(7):1205-1214. PubMed ID: 35856502 [TBL] [Abstract][Full Text] [Related]
28. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971 [TBL] [Abstract][Full Text] [Related]
29. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164 [TBL] [Abstract][Full Text] [Related]
30. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949 [No Abstract] [Full Text] [Related]
31. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Li B; Qiu J; Zheng Y; Shi Y; Zou R; He W; Yuan Y; Zhang Y; Wang C; Qiu Z; Li K; Zhong C; Yuan Y Ann Surg Open; 2021 Jun; 2(2):e057. PubMed ID: 37636551 [TBL] [Abstract][Full Text] [Related]
32. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. Deng M; Cai H; He B; Guan R; Lee C; Guo R Int J Surg; 2023 Nov; 109(11):3303-3311. PubMed ID: 37578432 [TBL] [Abstract][Full Text] [Related]
33. HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Liu J; Zhang J; Wang Y; Shu G; Lou C; Du Z Medicine (Baltimore); 2022 Dec; 101(51):e32390. PubMed ID: 36595819 [TBL] [Abstract][Full Text] [Related]
34. Pseudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization. An C; Yao W; Zuo M; Li W; Chen Q; Wu P Acad Radiol; 2024 Mar; 31(3):833-843. PubMed ID: 37487879 [TBL] [Abstract][Full Text] [Related]
35. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K Int J Surg; 2024 Jun; 110(12):7860-70. PubMed ID: 38869974 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis. Zhou SA; Zhou QM; Wu L; Chen ZH; Wu F; Chen ZR; Xu LQ; Gan BL; Jin HS; Shi N World J Gastrointest Oncol; 2024 Aug; 16(8):3672-3686. PubMed ID: 39171172 [TBL] [Abstract][Full Text] [Related]
37. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer]. Li R; Li WL; Yuan GS; Pang HJ; Li Q; Hu XY; Guo YB; Chen JZ; Zang MY Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1163-1168. PubMed ID: 38238949 [No Abstract] [Full Text] [Related]
38. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma. Huang Z; Chen T; Li W; Qiu J; Liu S; Wu Z; Li B; Yuan Y; He W Clin Exp Med; 2024 Jun; 24(1):138. PubMed ID: 38940944 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study. Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]